FI108138B - Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-[(N,N'-1,1')-substituoitu alkyleeni)-bis(3,3'-indolyyli)]-1H-pyrroli-2,5-dionijohdannaisten valmistamiseksi - Google Patents

Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-[(N,N'-1,1')-substituoitu alkyleeni)-bis(3,3'-indolyyli)]-1H-pyrroli-2,5-dionijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI108138B
FI108138B FI945706A FI945706A FI108138B FI 108138 B FI108138 B FI 108138B FI 945706 A FI945706 A FI 945706A FI 945706 A FI945706 A FI 945706A FI 108138 B FI108138 B FI 108138B
Authority
FI
Finland
Prior art keywords
mmol
bis
indolyl
dione
pyrrole
Prior art date
Application number
FI945706A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI945706A0 (fi
FI945706A7 (fi
Inventor
Michael Robert Jirousek
Iii John Hampton Mcdonald
Christopher John Rito
Jr William Francis Heath
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI945706A0 publication Critical patent/FI945706A0/fi
Publication of FI945706A7 publication Critical patent/FI945706A7/fi
Application granted granted Critical
Publication of FI108138B publication Critical patent/FI108138B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI945706A 1993-12-07 1994-12-02 Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-[(N,N'-1,1')-substituoitu alkyleeni)-bis(3,3'-indolyyli)]-1H-pyrroli-2,5-dionijohdannaisten valmistamiseksi FI108138B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16306093A 1993-12-07 1993-12-07
US16306093 1993-12-07
US31697394A 1994-10-03 1994-10-03
US31697394 1994-10-03

Publications (3)

Publication Number Publication Date
FI945706A0 FI945706A0 (fi) 1994-12-02
FI945706A7 FI945706A7 (fi) 1995-06-08
FI108138B true FI108138B (fi) 2001-11-30

Family

ID=26859318

Family Applications (3)

Application Number Title Priority Date Filing Date
FI945706A FI108138B (fi) 1993-12-07 1994-12-02 Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-[(N,N'-1,1')-substituoitu alkyleeni)-bis(3,3'-indolyyli)]-1H-pyrroli-2,5-dionijohdannaisten valmistamiseksi
FI20000516A FI20000516A7 (fi) 1993-12-07 2000-03-07 Bis-indolyylimaleimidijohdannaiset ja niiden valmistus
FI20011109A FI20011109A7 (fi) 1993-12-07 2001-05-28 Bis-indolyylisukkiini-imidijohdannaiset ja niiden valmistus

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI20000516A FI20000516A7 (fi) 1993-12-07 2000-03-07 Bis-indolyylimaleimidijohdannaiset ja niiden valmistus
FI20011109A FI20011109A7 (fi) 1993-12-07 2001-05-28 Bis-indolyylisukkiini-imidijohdannaiset ja niiden valmistus

Country Status (30)

Country Link
US (1) US5698578A (cs)
EP (1) EP0657458B1 (cs)
JP (2) JP3581731B2 (cs)
KR (1) KR100340159B1 (cs)
CN (2) CN1050844C (cs)
AT (1) ATE204579T1 (cs)
AU (1) AU687909B2 (cs)
BR (1) BR9404831A (cs)
CA (1) CA2137203C (cs)
CO (1) CO4340622A1 (cs)
CY (1) CY2413B1 (cs)
CZ (1) CZ291950B6 (cs)
DE (1) DE69428025T2 (cs)
DK (1) DK0657458T3 (cs)
ES (1) ES2162843T3 (cs)
FI (3) FI108138B (cs)
GR (1) GR3037087T3 (cs)
HU (1) HU219709B (cs)
IL (1) IL111850A (cs)
MY (1) MY125587A (cs)
NO (1) NO308798B1 (cs)
NZ (1) NZ270048A (cs)
PE (1) PE49195A1 (cs)
PL (1) PL182124B1 (cs)
PT (1) PT657458E (cs)
RU (1) RU2147304C1 (cs)
SG (1) SG63570A1 (cs)
TW (1) TW425397B (cs)
UA (1) UA44690C2 (cs)
YU (1) YU49200B (cs)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
JP4100708B2 (ja) * 1995-11-20 2008-06-11 イーライ リリー アンド カンパニー Ｎ，ｎ’−架橋ビスインドリルマレイミドの製造における新規中間体およびその用途
TR199800759T2 (xx) * 1995-11-20 2001-01-22 Eli Lilly And Company Protein Kinaz C �nhibit�r�.
CN1225634A (zh) * 1996-03-20 1999-08-11 伊莱利利公司 吲哚马来酰亚胺的合成
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
AU736333B2 (en) * 1996-05-01 2001-07-26 Eli Lilly And Company Therapeutic treatment for VEGF related diseases
KR20000065137A (ko) * 1996-05-01 2000-11-06 미시시피 스테이트 유니버시티 할로-치환된 단백질 키나제 c 억제제
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
EA199900244A1 (ru) * 1996-08-30 1999-10-28 Эли Лилли Энд Компани Применение ингибиторов протеинкиназы с для производства лекарственных препаратов для лечения заболеваний центральной нервной системы, связанных с вич инфекцией
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
AU4250697A (en) * 1996-08-30 1998-03-19 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
US5721272A (en) * 1996-11-18 1998-02-24 Eli Lilly And Company Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
JPH1135454A (ja) * 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd 抗腫瘍剤
CA2319418A1 (en) 1998-01-30 1999-08-05 Daiso Co., Ltd. Processes for preparing butanetriol derivatives
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
DE69911935T3 (de) * 1998-03-13 2008-02-07 The University Of British Columbia, Vancouver Granulatimide-derivate zur behandlung von krebs
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
JP2004526676A (ja) * 2000-12-08 2004-09-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド キナーゼ阻害剤として有用な大員複素環式化合物
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
JP2005516968A (ja) * 2001-12-29 2005-06-09 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
JP4928261B2 (ja) 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド モチリン受容体の大環状拮抗薬
EP1653973A1 (en) 2003-08-08 2006-05-10 Novartis AG Combinations comprising staurosporines
RU2373201C2 (ru) * 2004-01-19 2009-11-20 Новартис Аг Индолилмалеимидные производные
CN1964706A (zh) * 2004-03-17 2007-05-16 拉斯·M·拉森 通过抑制视觉周期预防视网膜病
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US7759331B2 (en) 2006-03-10 2010-07-20 Janssen Pharmaceutica Nv Pyridine-containing macroheterococylic compounds as kinase inhibitors
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
RU2441000C2 (ru) * 2009-11-27 2012-01-27 Общество с ограниченной ответственностью "Молекулярные Технологии" 4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
CN102821759A (zh) 2010-03-30 2012-12-12 诺华有限公司 用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
AU2013352379B2 (en) 2012-11-29 2018-09-06 Novartis Ag Pharmaceutical combinations
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
USRE50634E1 (en) 2014-01-24 2025-10-14 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CN107735399B (zh) 2015-07-02 2021-01-26 特普医药公司 作为蛋白质激酶的调节剂的手性二芳基大环
AU2016289454B2 (en) 2015-07-06 2020-07-09 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
EP3325488B1 (en) * 2015-07-21 2020-06-24 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
CN106854141A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4-氯甲苯化合物的合成方法
CN107778148A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种溴化苄衍生物的合成方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
SG11202005590PA (en) 2017-12-19 2020-07-29 Turning Point Therapeutics Inc Macrocyclic compounds for treating disease
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof
WO2024159211A1 (en) * 2023-01-27 2024-08-02 Mellicell, Inc. Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement
WO2024220957A1 (en) * 2023-04-21 2024-10-24 4M Therapeutics Inc. Polymorphs of n-desmethyl ruboxistaurin and salts thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
EP0303697B1 (en) * 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
FR2614022B1 (fr) * 1987-04-15 1989-12-01 Roussel Uclaf Nouveaux derives 17-aza de 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et ces compositions les renfermant
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
IL89167A (en) * 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA2015996C (en) * 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
TW214553B (cs) * 1991-04-11 1993-10-11 Schering Corp
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5589472A (en) * 1992-09-25 1996-12-31 Vice; Susan F. Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
FI945706A0 (fi) 1994-12-02
HUT71130A (en) 1995-11-28
AU7918894A (en) 1995-06-15
KR100340159B1 (ko) 2002-11-23
IL111850A (en) 2002-11-10
IL111850A0 (en) 1995-03-15
SG63570A1 (en) 1999-03-30
MY125587A (en) 2006-08-30
GR3037087T3 (en) 2002-01-31
EP0657458B1 (en) 2001-08-22
JP2004269543A (ja) 2004-09-30
FI20011109L (fi) 2001-05-28
HK1013827A1 (en) 1999-09-10
YU49200B (sh) 2004-09-03
CO4340622A1 (es) 1996-07-30
HU219709B (hu) 2001-06-28
CY2413B1 (en) 2004-11-12
NZ270048A (en) 1996-11-26
YU70494A (sh) 1997-03-07
PL182124B1 (pl) 2001-11-30
ATE204579T1 (de) 2001-09-15
CN1111247A (zh) 1995-11-08
CZ301894A3 (en) 1995-06-14
JPH07215977A (ja) 1995-08-15
ES2162843T3 (es) 2002-01-16
CN1055089C (zh) 2000-08-02
FI20011109A7 (fi) 2001-05-29
DE69428025D1 (de) 2001-09-27
KR950018010A (ko) 1995-07-22
FI945706A7 (fi) 1995-06-08
CN1050844C (zh) 2000-03-29
AU687909B2 (en) 1998-03-05
EP0657458A1 (en) 1995-06-14
NO944643D0 (no) 1994-12-02
BR9404831A (pt) 1995-08-08
RU94042922A (ru) 1996-12-27
RU2147304C1 (ru) 2000-04-10
PE49195A1 (es) 1996-01-06
PL306084A1 (en) 1995-06-12
US5698578A (en) 1997-12-16
UA44690C2 (uk) 2002-03-15
DE69428025T2 (de) 2002-05-29
PT657458E (pt) 2002-02-28
JP3581731B2 (ja) 2004-10-27
CN1220266A (zh) 1999-06-23
CA2137203A1 (en) 1995-06-08
HU9403468D0 (en) 1995-02-28
CZ291950B6 (cs) 2003-06-18
CA2137203C (en) 2006-11-28
NO308798B1 (no) 2000-10-30
TW425397B (en) 2001-03-11
FI20000516A7 (fi) 2000-03-07
DK0657458T3 (da) 2001-10-29
NO944643L (no) 1995-06-08

Similar Documents

Publication Publication Date Title
FI108138B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-[(N,N'-1,1')-substituoitu alkyleeni)-bis(3,3'-indolyyli)]-1H-pyrroli-2,5-dionijohdannaisten valmistamiseksi
US5621098A (en) Process for preparing bis-indolyl macrocycles
CA2252701C (en) Halo-substituted protein kinase c inhibitors
US5843935A (en) Protein kinase C inhibitors
HK1013827B (en) Protein kinase c inhibitors
MXPA98009014A (en) Inhibitors of protein cinasa c, halo-sustitui
CN1223658A (zh) 卤代的蛋白激酶c抑制剂

Legal Events

Date Code Title Description
MA Patent expired